AshkanEmadiMDPhD

Hematologic Oncology, Clinical Pharmacology

Professor of Medicine and Pharmacology at University of Maryland School of Medicine; Associate Director for Clinical Research Greenebaum Comprehensive Cancer Center; Director Translational Genomics Laboratory

Join to view full profile

Dr. Emadi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Emadi's full profile

Already have an account?

Office
1 Medical Center Dr
Morgantown, WV 26506
Phone+1 304-598-4500

Fax+1 410-328-6896

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 2005 - 2007
University of Kentucky College of MedicineInternship, Internal Medicine, 2004 - 2005
Illinois Institute of TechnologyPhD, Organic Chemistry, 2000 - 2004
Tehran University of Medical Sciences School of MedicineClass of 1999

Certifications & Licensure

MD State Medical License 2006 - 2026
WV State Medical License 2024 - 2026
OH State Medical License 2005 - 2007
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Clinical Trials

Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2012 Jan 13
Completed
Phase 1
1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML) Start of enrollment: 2014 Apr 01
Completed
Phase 1
Trial of Imatinib for Hospitalized Adults With COVID-19 Start of enrollment: 2020 Jun 02
Active, not recruiting
Phase 3
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) Start of enrollment: 2021 Mar 10
Active, not recruiting
Phase 1
Roles: Principal Investigator
Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL Start of enrollment: 2021 Jun 11
Active, not recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

18 citations
Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
Najeebah A. Bade, Crystal Lu, Ciera L Patzke, Maria R. Baer, Vu H. Duong
Journal of Oncology Pharmacy Practice. 2020-01-01
176 citations
Predictive Value of Factor V Leiden and Prothrombin G20210A in Adults With Venous Thromboembolism and in Family Members of Those With a Mutation: A Systematic Review
Jodi B Segal, Daniel J. Brotman, Alejandro J Necochea, Ashkan Emadi, Lipika Samal
JAMA. 2009-06-17
570 citations
Cyclophosphamide and cancer: golden anniversary.
Ashkan Emadi, Richard J. Jones, Robert A. Brodsky
Nature Reviews. Clinical Oncology. 2009-09-29

Abstracts/Posters

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
Ashkan Emadi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Mye...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

MacroGenics : Flotetuzumab (CD123 X CD3) as Salvage Therapy for PIF and ER AML (Aldoss)December 7th, 2020
$50 Million Gift Will Spur Development of Morgantown Cancer CenterApril 7th, 2024

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member
American Medical Association - AMA
Member